Catalog No.
Product Name
Application
Product Information
Citations
-
Dual Thromboxane Synthase Inhibitor and Receptor Antagonist
Ridogrel is a dual thromboxane A2 synthase inhibitor and receptor antagonist. This compound exhibits potent antiplatelet activity, making it useful in research focused on cardiovascular diseases and thrombotic disorders. Additionally, Ridogrel displays anti-inflammatory properties, providing a valuable tool for studying inflammation-related pathways in various biological contexts. -
Thromboxane-prostanoid (TP) Receptor Antagonist
SQ 29548 is a selective thromboxane-prostanoid (TP) receptor antagonist. This compound inhibits TP receptor signaling, which plays a critical role in various physiological and pathological processes, including vascular function, platelet aggregation, and inflammation. Its primary applications include research in cardiovascular diseases, thrombus formation, and the study of prostanoid biology. SQ 29548 serves as a valuable tool for investigating the therapeutic potential of modulating TP receptor activity. -
EP4 Antagonist
MF-766 is a potent and selective EP4 antagonist, exhibiting a Ki value of 0.23 nM. It functions as a full antagonist in functional assays, displaying an IC50 of 1.4 nM, which slightly increases to 1.8 nM in the presence of 10% human serum. This reagent is valuable for research related to cancer and inflammatory diseases, facilitating the exploration of EP4 pathways in therapeutic contexts. -
Prostaglandin Receptor Inhibitor
Ascorbyl tetra-2-hexyldecanoate is a lipophilic derivative of L-ascorbic acid that functions as a prostaglandin receptor inhibitor. This compound demonstrates protective effects on HaCaT keratinocytes, maintaining cell viability against UVB and oxidative stress while decreasing the production of inflammatory mediators IL-1α and prostaglandin E2 (PGE2). In vivo studies show that topical application enhances epidermal thickness, increases stratum corneum hydration, and improves skin texture, highlighting its potential for formulating skin whitening agents in cosmetic applications. -
EP4 Agonist
TCS 2510 is a selective agonist of the EP4 receptor, known for its potential to modulate various biological processes. This compound exhibits significant activity in the context of metabolic diseases, making it a valuable tool for research applications aimed at understanding the underlying mechanisms of these disorders. -
Active Metabolite of Misoprostol
Misoprostol acid is the active metabolite of Misoprostol, a synthetic analogue of prostaglandin E1 (PGE1). This compound is rapidly formed through de-esterification in the gastrointestinal tract following oral administration and is effective in preventing non-steroidal anti-inflammatory drug-induced gastric ulcers. Additionally, Misoprostol acid plays a significant role in obstetric applications, particularly in the induction of labor. -
EP3 Receptor Agonist
Sulprostone is a potent and selective agonist of the EP3 receptor, a critical target in various physiological processes. This prostaglandin E2 (PGE2) analog exhibits antiulcer and nonsteroidal abortifacient properties. Sulprostone is relevant for research applications focused on pregnancy termination and the management of hemorrhages during delivery. -
Prostaglandin Receptor Agonist
ONO-AE 248 is a selective agonist of the EP3 prostaglandin receptor, exhibiting notable cardioprotective properties. It significantly reduces myocardial infarction size by specifically targeting the EP3α receptor in murine models, with its beneficial effects occurring independently of hemodynamic changes. The protective mechanism may involve the activation of protein kinase C and the opening of K(ATP) channels, highlighting its potential utility in cardiovascular research. -
TxA2 Synthase/Receptor Inhibitor
Picotamide is a dual inhibitor of thromboxane A2 (TxA2) synthase and its receptor, exhibiting significant antiplatelet activity. This compound is effective in reducing microalbuminuria and inhibiting the growth of carotid plaques, particularly in diabetic models. Picotamide is a valuable tool for investigating both acute and chronic cardiovascular diseases, aiding research into therapeutic interventions for these conditions. -
EP3 Antagonist
EP3 antagonist 3 is a potent and selective antagonist of the EP3 receptor, exhibiting a pKi value of 8.3. This compound demonstrates excellent pharmacokinetic properties, making it suitable for in vivo studies. EP3 antagonist 3 is primarily utilized in research related to overactive bladder (OAB), providing valuable insights into potential therapeutic interventions. -
EP1 Antagonist
SC 51089 free base acts as a selective antagonist of the prostaglandin E2 EP1 receptor, displaying inhibitory constants (Kis) of 1.3 μM for EP1, 11.2 μM for TP, 17.5 μM for EP3, and 61.1 μM for FP receptors. This compound demonstrates notable neuroprotective activity, making it valuable for research in neurobiology and inflammation studies. Its specificity towards the EP1 receptor positions SC 51089 free base as an important tool for investigating the effects of prostaglandin signaling in various biological systems. -
EP2 Inhibitor
TG8-260 is a selective EP2 antagonist designed to mitigate the effects of inflammation in both central nervous system and peripheral diseases. This compound effectively reduces neuroinflammation and gliosis in the hippocampus of rats following pilocarpine-induced status epilepticus. With a plasma half-life of 2.14 hours and an oral bioavailability of 77.3%, TG8-260 also demonstrates potent inhibition of CYP450. Its ability to inhibit EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia makes it a valuable tool for investigating anti-inflammatory pathways in various animal models of peripheral inflammatory conditions. -
EP4 Receptor Agonist
EP4 Receptor Agonist 2 is a potent agonist of the EP4 receptor, exhibiting an EC50 value of 0.8 nM. This compound has demonstrated selectivity with Ki values of >100,000, 38,000, and 3.1 nM for the EP2, EP3, and EP4 receptors, respectively. It is a valuable tool for studying the role of EP4 signaling in various biological processes and exploring potential therapeutic applications in inflammatory and cardiovascular diseases. -
TxA2/PGH2 Receptor Antagonist
Ifetroban sodium is an orally active antagonist of the thromboxane A2 (TXA2) and prostaglandin H2 (PGH2) receptors. It exhibits significant antiplatelet activity and effectively inhibits tumor cell migration while having no impact on cell proliferation. This compound is valuable in research related to myocardial ischemia, hypertension, stroke, thrombosis, and cardiomyopathy. -
FP Receptor Agonist
Tafluprost acid is a selective agonist of the prostanoid FP receptor, demonstrating high affinity with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Its binding affinity for the prostanoid EP3 receptor is significantly lower, with an IC50 of 67 nM, indicating a preferential interaction with the FP receptor. Tafluprost acid is primarily utilized in glaucoma research, making it a valuable tool for studies focused on intraocular pressure regulation and ocular pharmacology. -
EP3 Receptor Antagonist
L-826266 is a selective and competitive antagonist of the EP3 receptor. This compound exhibits potent inhibition of EP3-mediated signaling, making it valuable for investigating pathways involved in convulsive disorders and other related conditions. Its targeted mechanism of action supports research into the role of prostaglandin signaling in neuroinflammation and seizure activity. -
EP2 Receptor Antagonist
EP2 receptor antagonist-3 is a selective antagonist of the EP2 receptor, exhibiting an IC50 of 8 nM in human EP2 SPA assays and 50 nM in human EP2 cAMP assays. It enhances macrophage-mediated clearance of Amyloid-β plaques, making it a valuable tool for research into Alzheimer's disease and related neurodegenerative disorders. This compound can aid in understanding the role of EP2 receptors in immune response and amyloid pathology. -
Prostaglandin Receptor Antagonist
BAY-6672 hydrochloride is a potent and selective antagonist of the human Prostaglandin F (FP) receptor, exhibiting an IC50 of 11 nM. This compound is primarily utilized in the research of inflammatory processes and pain modulation, making it valuable for studies in pharmacology and therapeutic development. Its selective action on FP receptors provides insights into prostaglandin signaling pathways and their implications in various pathophysiological conditions. -
Vasodilator
Prostaglandin F1α is a potent vasodilator that primarily targets smooth muscle tissue. It has demonstrated the ability to induce relaxation of vascular smooth muscle, leading to reduced blood pressure. This compound is widely used in cardiovascular research to study its effects on vascular tone and the regulation of blood flow. -
EP2 Antagonist
EP2 Receptor Antagonist-1 is a potent allosteric antagonist of the prostaglandin EP2 receptor, exhibiting reversible binding and agonist-dependent activity. This compound demonstrates significant anti-inflammatory effects, making it valuable for research focusing on inflammatory pathways and conditions. Its ability to selectively inhibit EP2 receptor activity positions it as a useful tool in pharmacological studies aimed at exploring novel therapeutic strategies. -
Prostanoid Derivative
11β-Prostaglandin E2, a prostanoid derivative, acts as a selective inhibitor of [3H]PGE2 binding to hypothalamic membranes in rat models, exhibiting a Ki of 53.3 nM. This compound is valuable for studying the physiological roles of prostaglandins, particularly in neurobiology and endocrinology research contexts. Its ability to modulate prostaglandin signaling pathways makes it a significant tool for exploring inflammatory responses and reproductive biology. -
EP4 Receptor Agonist
CAY10580 is a potent and selective agonist of the prostaglandin EP4 receptor, with a Ki value of 35 nM. This compound demonstrates significant biological activity in modulating inflammatory responses and vascular functions. CAY10580 is primarily utilized in research to investigate the role of EP4 signaling in various physiological and pathological processes, making it a valuable tool for studies in immunology and cardiovascular research. -
EP1/EP3 Receptor Agonist
17-Phenyl-ω-trinor-PGE2 is an agonist for the EP1 and EP3 receptors. This compound showcases significant biological activity by inhibiting PAF-induced aggregation of human platelet-rich plasma and modulating Cyclic AMP production in response to Cicaprost. It is a valuable tool for research involving platelet function and receptor signaling pathways. -
Prostacyclin Receptor Antagonist
BAY 73-1449 is a highly potent and selective antagonist of the prostacyclin receptor (IP), demonstrating an IC50 of less than 0.1 nM in cAMP assays using human HEL cells and rat dorsal root ganglion (DRG) neurons. This compound serves as a valuable tool in research aimed at elucidating the role of prostacyclin signaling in cardiovascular physiology, particularly in studies focused on blood pressure regulation. -
DP2 Receptor Agonist
13,14-Dihydro-15-keto prostaglandin D2 is a selective agonist of the DP2 receptor, derived from the 15-hydroxyl PGDH metabolic pathway. This compound is known to inhibit ion flux in canine colonic mucosa preparations, thereby impacting various physiological processes. It serves as a valuable tool for research applications exploring inflammation, allergic responses, and other DP2 receptor-mediated functions in biological systems. -
Thromboxane Synthase Inhibitor
Dazoxiben hydrochloride is a potent thromboxane synthase inhibitor that exhibits oral bioavailability. It effectively suppresses thromboxane production, a key factor in platelet aggregation and vascular smooth muscle contraction. This compound is utilized in research focused on cardiovascular diseases and conditions related to thrombosis and inflammation. -
Pulmonary Vasodilator Prodrug
Treprostinil palmitil is a long-acting pulmonary vasodilator prodrug that targets the inhibition of hypoxia-induced pulmonary vasoconstriction. Formulated in lipid nanoparticles, it exhibits sustained lung presence while minimizing systemic exposure. Research applications include the investigation of pulmonary arterial hypertension and interstitial lung disease, as well as the capacity to inhibit pulmonary vascular remodeling induced by Su/Hx challenge in animal models. Additionally, Treprostinil palmitil is associated with cough induction. -
TXA2 Receptor Antagonist
Daltroban is a selective thromboxane A2 (TXA2) receptor antagonist. It enhances intracellular calcium levels in vascular smooth muscle cells, contributing to its pharmacological effects. Research demonstrates that Daltroban offers protective benefits in models of reperfusion injury, making it a valuable tool for studies related to cardiovascular health and vascular smooth muscle function. -
PGD2 Antagonist
BW A868C is a selective and potent competitive antagonist of prostaglandin D2 (PGD2). This hydantoin derivative, structurally related to BW245C, demonstrates high specificity without affecting other prostaglandin receptors, including IP, EP1, EP2, TP, and FP. BW A868C is valuable for research applications involving PGD2 pathways and its role in various physiological and pathological processes. -
EP4 Receptor Antagonist
AAT-008 is a selective and orally active antagonist of the prostaglandin EP4 receptor, exhibiting Ki values of 0.97 nM for recombinant human EP4 and 6.1 nM for recombinant rat EP4. This compound demonstrates significant tumor growth delay in murine models of CT26WT colon tumors when used in conjunction with radiotherapy. AAT-008 is valuable for investigating acute and chronic inflammatory pain, as well as cancer-related research applications. -
EP4 Antagonist
EP4-IN-1 is a selective antagonist of the prostanoid EP4 receptor, primarily involved in modulating inflammatory responses and immune regulation. This compound demonstrates significant potential in the fields of tumor immunology and anti-inflammatory analgesia research. By inhibiting EP4 signaling, EP4-IN-1 may contribute to the development of novel therapeutic strategies for cancer and chronic pain management. -
EP2 Receptor Antagonist
EP2 receptor antagonist-2 (CID891729) is a selective antagonist of the EP2 receptor, effectively inhibiting PGE2-induced receptor activation. This compound also demonstrates the ability to suppress lactate dehydrogenase (LDH) release triggered by N-methyl-D-aspartate (NMDA). It is valuable for research applications focused on inflammatory responses and neuronal excitotoxicity. -
EP2/DP1/IP Agonist
Treprostinil diethanolamine is a potent agonist of the EP2, DP1, and IP receptors, exhibiting Ki values of 3.6 nM for EP2, 4.4 nM for DP1, and 32.1 nM for IP. This compound plays a critical role in elevating cAMP levels, contributing to vascular homeostasis. Treprostinil diethanolamine is particularly effective in inducing vasodilation of human pulmonary arteries, making it a valuable reagent for research in cardiovascular and pulmonary disease pathways. -
EP4 Agonist
11-Deoxy Prostaglandin E2 is a selective agonist of the EP4 receptor, exhibiting an EC50 of 0.66 nM. This analog of prostaglandin E2 plays a significant role in modulating various biological processes. It is valuable for research applications related to bone healing, heart failure, and other conditions associated with receptor activation. -
CRTh2 Antagonist
LAS191859 is a potent and selective antagonist of the CRTh2 receptor, exhibiting an IC50 value of 9.58 nM in human CRTh2 assays. This compound is primarily used in research related to chronic asthma, where it may help elucidate the role of CRTh2 in inflammatory pathways and potential therapeutic strategies. Its oral bioactivity makes it a valuable tool for investigating the modulation of immune responses associated with respiratory conditions. -
Prostacyclin Receptor Antagonist
RO3244794 is a potent and selective antagonist of the prostacyclin receptor (IP receptor), demonstrating a pKi value of 7.7 in human platelets and 6.9 in a recombinant IP receptor system. This compound shows significant analgesic and anti-inflammatory properties, making it a valuable tool for researchers investigating pain mechanisms and inflammatory conditions. Its specificity and efficacy contribute to its potential applications in pharmacological studies related to cardiovascular diseases and other related disorders. -
CRTH2 Antagonist
CAY10471 is a selective antagonist of the prostaglandin D2 receptor CRTH2, demonstrating potent oral bioactivity. It effectively attenuates the progression of tubulointerstitial fibrosis and mitigates chronic contact hypersensitivity in animal models. This compound is valuable for research into inflammatory diseases and potential therapeutic pathways involving the CRTH2 receptor. -
EP2 receptor Agonist
PGN-9856 is a selective agonist of the EP2 receptor, exhibiting high affinity with a pKi of 8.3 or greater. This potent non-prostanoid compound demonstrates significant biological activity, with an EC50 value of 8.5 or higher, making it effective in anti-inflammatory and anti-glaucoma research applications. PGN-9856 serves as a valuable tool for exploring the therapeutic potential of targeting the EP2 receptor in various pharmacological studies. -
NSAID
Alclofenac is a non-steroidal anti-inflammatory drug (NSAID) that acts as a selective inhibitor of prostaglandin H2 synthase. It exhibits significant anti-inflammatory and analgesic properties, making it suitable for studies related to rheumatoid arthritis, degenerative joint disease, and ankylosing spondylitis. This compound is valuable for research into the mechanisms of pain and inflammation pathways. -
Thromboxane Synthase Inhibitor
Furegrelate sodium is a selective thromboxane synthase inhibitor, demonstrating significant inhibition of human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. This compound is being investigated for its potential as an antiplatelet agent, making it a valuable tool for research in cardiovascular diseases and platelet function studies. Its oral availability enhances its applicability in preclinical and clinical settings, contributing to advancements in antiplatelet therapy development. -
EP4 Receptor Antagonist
EP4 receptor antagonist 2 is a tricyclic spiro-based compound that selectively targets the EP4 receptor. It exhibits stable microsomal properties, making it suitable for in vitro studies. This compound is primarily utilized in research focused on inflammation and pain pathways, providing insights into therapeutic interventions for various diseases associated with EP4 receptor activation. -
Vasoconstrictor
U-44069 is a stable analogue of prostaglandin H2 that functions as a potent vasoconstrictor. It effectively induces calcium influx in preglomerular vessels, making it a valuable tool for studying vascular physiology and related signaling pathways. This compound is useful for research applications focused on vascular response and regulation. -
Lower Intraocular Pressure Agent
Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue designed to lower intraocular pressure (IOP). It operates by enhancing uveoscleral outflow through bimatoprost activation while facilitating conventional outflow via NO release. This compound is valuable for research focused on ocular hypertension and glaucoma, making it a significant tool for studying IOP regulation and potential therapeutic interventions. -
PGHS1 Inhibitor
Satigrel is a selective inhibitor of prostaglandin H synthase 1 (PGHS1), primarily targeting platelet aggregation. It effectively inhibits collagen- and arachidonic acid-induced platelet aggregation by blocking thromboxane A2 synthesis. With an IC50 of 0.081 μM for PGHS1 and 5.9 μM for PGHS2, Satigrel also demonstrates inhibitory activity against Type III, Type V, and Type II phosphodiesterases, with IC50 values of 15.7 μM, 39.8 μM, and 62.4 μM, respectively. This compound is valuable for research into platelet function and thrombotic diseases. -
F2α Receptor Antagonist
AS604872 is a potent and selective antagonist of the prostaglandin F2α receptor (FP), exhibiting a Ki of 35 nM in human assays. This compound is known to inhibit uterine contractions and may delay labor, making it a valuable tool for research related to reproductive health and uterine physiology. Its oral bioactivity further supports its utility in in vivo studies. -
PGF2α Metabolite
15-keto-Prostaglandin F2α is a metabolite of Prostaglandin F2α, functioning primarily as an agonist for the prostaglandin F receptor (FP receptor). This compound is essential for understanding the physiological roles of prostaglandin signaling, particularly in the regulation of labor onset and progression. It serves as a valuable tool in research applications exploring reproductive biology and related therapeutic interventions. -
Prostaglandin Receptor
ONO-8713 is a selective antagonist of the prostaglandin E receptor subtype EP1. This compound inhibits EP1 receptor activity, which plays a critical role in various physiological processes, including pain perception and inflammation. ONO-8713 is utilized in research focused on investigating the role of prostaglandin signaling in pathophysiological conditions and developing novel anti-inflammatory therapies. -
Endogenous Hormone
Prostaglandin F2α ethanolamide is an ethanolamide that acts on G protein-coupled receptors. This compound has been identified as a potential nociceptive mediator in the spinal cord and plays a role in reproductive physiology, particularly as a luteinizing hormone in sheep. It is useful for research applications exploring pain mechanisms and reproductive hormone signaling pathways. -
Prostaglandin E2 Inhibitor
Thielavin A is a selective inhibitor of prostaglandin E2 biosynthesis, derived from the fungus Thielavia terricola. It specifically targets the conversion of arachidonic acid to prostaglandin H2, thereby disrupting the prostaglandin synthesis pathway. Despite its inhibition of prostaglandin E2, Thielavin A exhibits minimal anti-inflammatory effects upon intravenous or oral administration, making it a valuable tool for studying prostaglandin-related biological processes and inflammation research. -
Isomer
(Z)-ONO 1301 is the isomer of ONO 1301, serving as an important experimental control in research. ONO 1301, a prostaglandin I2 mimetic, functions as a long-acting prostacyclin agonist with thromboxane-synthase inhibitory properties. It has been shown to enhance the production of hepatocyte growth factor (HGF) in multiple cell types and to improve ischemia-induced left ventricular dysfunction in murine, rat, and porcine models. This compound is valuable for studies focused on cardiovascular protection and tissue regeneration.
